ACTG A5142

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 A5142是一项III期、随机、三组、开放标签研究，比较了以下方案用于HIV感染初始治疗的有效性： 基于非核苷逆转录酶抑制剂（NNRTI）的方案（依法韦仑[EFV]+司他夫定缓释剂[d4 T XR]（或齐多夫定[ZDV]或富马酸替诺福韦酯[TDF]+拉米夫定[3 TC]） 利托那韦（RTV）-增强蛋白酶抑制剂（PI）为基础的方案（洛匹那韦/利托那韦[LPV/RTV]+ d4 T XR [或ZDV或TDF]+3 TC） 核苷逆转录酶抑制剂（NRTI）保留方案（EFV + LPV/RTV）

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5142 is a phase III, randomized, three-arm, open-label study comparing the effectiveness of the following regimens for the initial treatment of HIV infection: Nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen (efavirenz [EFV] plus stavudine extended release [d4T XR] (or zidovudine [ZDV] or tenofovir disoproxil fumarate [TDF]) plus lamivudine [3TC]) Ritonavir (RTV)-enhanced protease inhibitor (PI)-based regimen (lopinavir/ritonavir [LPV/RTV] plus d4T XR [or ZDV or TDF] plus 3TC) Nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen (EFV plus LPV/RTV)